[« ReNAissance » of biotherapies with RNA].
| Autor: | Pitard B; Nantes Université, Université d'Angers, Immunology and New Concepts in Immunotherapy (INCIT), Inserm UMR-S 1302, CNRS EMR6001, Nantes, France., Pitard I; In-Cell-Art, Nantes, France. |
|---|---|
| Jazyk: | francouzština |
| Zdroj: | Medecine sciences : M/S [Med Sci (Paris)] 2024 Jun-Jul; Vol. 40 (6-7), pp. 525-533. Date of Electronic Publication: 2024 Jul 08. |
| DOI: | 10.1051/medsci/2024079 |
| Abstrakt: | Many diseases originate from either the absence or defective expression of a given protein. For some of them, the lacking protein is secreted or can be taken up by cells when delivered exogenously. In such cases, therapies initially involved administering the physiological protein extracted from human tissues. Subsequently, genetic engineering enabled the production of proteins through cell fermentation after introducing the corresponding gene. For many other pathologies, the deficient protein cannot be delivered exogenously. Thus, an endogenous production of the therapeutic protein by the cells themselves is necessary. Messenger RNA (mRNA) technology, like its predecessor DNA, aims to supplement the genetic information needed to produce the therapeutic protein within the cells. However, unlike DNA-based therapies, mRNA transfer allows for transient expression of the protein of interest, which offers an advantage in numerous pathologies. Nonetheless, mastering the quantity, quality, and spatio-temporal regulation of protein production encoded by therapeutic mRNA remains a significant challenge for the development of this approach. (© 2024 médecine/sciences – Inserm.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|